ZOM — Zomedica Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapNeutral
- $190.99m
- $71.52m
- $18.93m
- 20
- 39
- 48
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 1.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.27% | ||
| Return on Equity | -7.32% | ||
| Operating Margin | -121.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 4.13 | 18.93 | 31.13 | 43.06 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).
Directors
- Jeffrey Rowe NEC (65)
- Larry Heaton CEO (64)
- Ann Cotter CFO (51)
- Stephanie Morley COO (46)
- Robert Cohen DRC (63)
- Sean Whelan DRC (50)
- Christopher MacLeod IND (51)
- Johnny Powers IND (60)
- Rodney Williams IND (60)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 7th, 2013
- Public Since
- October 28th, 2013
- No. of Employees
- 85
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 979,949,668
- Address
- 100 Phoenix Drive, Suite 125, ANN ARBOR, 48108
- Web
- https://zomedica.com/
- Phone
- +1 7343692555
- Auditors
- Grant Thornton LLP
Upcoming Events for ZOM
Q2 2023 Zomedica Corp Earnings Release
Q3 2023 Zomedica Corp Earnings Release
Similar to ZOM
Actinium Pharmaceuticals
NYSE MKT
Agex Therapeutics
NYSE MKT
AIM ImmunoTech
NYSE MKT
Ampio Pharmaceuticals
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
What is the Zomedica share price?
As of Today at 07:25 UTC, shares in Zomedica are trading at $0.19. This share price information is delayed by 15 minutes.
How has the Zomedica share price performed this year?
Shares in Zomedica last closed at $0.19 and the price had moved by -17.45% over the past 365 days. In terms of relative price strength the Zomedica share price has underperformed the S&P500 Index by -18.38% over the past year.
What are the analyst and broker recommendations for Zomedica?
The overall consensus recommendation for Zomedica is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zomedica dividend yield?
Zomedica does not currently pay a dividend.
Does Zomedica pay a dividend?
Zomedica does not currently pay a dividend.
When does Zomedica next pay dividends?
Zomedica does not currently pay a dividend.
How do I buy Zomedica shares?
To buy shares in Zomedica you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zomedica?
As of the previous close price of $0.19, shares in Zomedica had a market capitalisation of $190.99m.
Where are Zomedica shares listed?
Here are the trading details for Zomedica:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: ZOM
What kind of share is Zomedica?
Based on an overall assessment of its quality, value and momentum Zomedica is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zomedica share price forecast for 2023?
The analyst consensus target price for shares in Zomedica is $0.44. That is 125.76% above the last closing price of $0.19.
Analysts covering Zomedica currently have a consensus Earnings Per Share (EPS) forecast of -$0.01 for the next financial year.
What is the trend in the Zomedica share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zomedica. Over the past six months, its share price has underperformed the S&P500 Index by -11.17%.
As of the last closing price of $0.19, shares in Zomedica were trading -13.98% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zomedica PE Ratio?
The Zomedica PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zomedica?
Zomedica's management team is headed by:
- Jeffrey Rowe - NEC
- Larry Heaton - CEO
- Ann Cotter - CFO
- Stephanie Morley - COO
- Robert Cohen - DRC
- Sean Whelan - DRC
- Christopher MacLeod - IND
- Johnny Powers - IND
- Rodney Williams - IND